Conference on Clinical Cancer Research
The 2009 Conference on Clinical Cancer Research, hosted by the Engelberg Center for Health Care Reform and Friends of Cancer Research, brought together distinguished members of the cancer community for in-depth discussions of critical issues at the intersection of clinical research and policy.
The all-day event on September 14 convened leaders from the National Cancer Institute (NCI), academia, patient advocacy organizations, the Food and Drug Administration (FDA), and various industry organizations, to discuss specific research and policy issues, as well as build consensus around solutions to critical questions regarding the future of clinical cancer research.
Opening remarks were delivered by NCI Director John Niederhuber, with keynote remarks offered by FDA Commissioner Margaret Hamburg. Interactive panel discussions focused on optimal data collection for clinical trials, development and approval of targeted therapies, and development of combination therapies targeting multiple pathways.
Agenda
Welcome
Mark B. McClellan
Former Brookings Expert
Mark McClellan is a senior fellow and director of the Health Care Innovation and Value Initiative at Brookings. He has written a number of publications on care delivery reform, physician payment reform, and accountable care implementation in the U.S. and abroad.
John Niederhuber
Director, National Cancer Institute
Panel 1: Data Submission Standards and Evidence Requirements
Richard Schilsky
Chief Medical Officer - American Society of Clinical Oncology
Gwen Fyfe
Consultant
Jeffrey Abrams
National Cancer Institute
Robert Erwin
Marti Nelson Cancer Foundation
Robert Temple
Deputy Director for Clinical Science, Center for Drug Evaluation and Research - U.S. Food and Drug Administration
Panel 2: Blinded Independent Central Review of PFS Endpoints
Moderator: Daniel Sargent
Mayo Clinic
Will Bushnell
GlaxoSmithKline
Ohad Amit
GlaxoSmithKline
Lori Dodd
National Institute of Allergy and Infectious Diseases
Nancy Roach
C3: Colorectal Cancer Coalition
Richard Padzur
Food and Drug Administration
Keynote Address
Introduction: Ellen Sigal
Friends of Cancer Research
Margaret Hamburg
Commissioner - U.S. Food and Drug Administration
Panel 3: Accelerating Development and Approval of Targeted Cancer Therapies
Anna Barker
National Cancer Institute
David Epstein
Novartis
Co-Moderator: Stephen Friend
President, Sage Bionetworks
Cindy Geoghegan
Patient and Partners
David Sidransky
The Johns Hopkins University School of Medicine
Raymond Woosley
Critical Path Institute
Patricia Keegan
Food and Drug Administration
Panel 4: Development of Two Novel Therapeutics Targeting Multiple Pathways
Moderator: Charles Erlichman
Mayo Clinic
Adam Clark
Director, Scientific and Federal Affairs, Faster Cures
Matthew Ellis
Washington University in St. Louis
Stuart Lutzker
Genentech
James Zwiebel
National Cancer Institute
Janet Woodcock
Director, Center for Drug Evaluation and Research - US Food and Drug Administration
Summary and Closing Remarks
